Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to requirement of Regulation 24A(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2020-21 issued by KJB & Co. LLP, Practicing Company Secretaries. This is for your information and records. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Press Release relating to collaboration for a clinical trial of investigational oral anti-viral drug Molnupiravir for COVID-19 by five major pharma companies. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to collaboration for a clinical trial of investigational oral anti-viral drug Molnupiravir for COVID-19 by five major pharma companies. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosure Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the details of related party transactions on consolidated basis for the half year ended March 31, 2021 in the format specified in the relevant accounting standards for annual results. This is for your information and record. Sun Pharmaceutical Industries Ltd - 524715 - Closure of Trading Window
This is to inform you that in compliance with the Company's Code of Conduct for prevention of Insider Trading, the window closure for trading by Designated Persons of the Company (alongwith his/her immediate relatives or any person with whom he/she shares a material financial relationship), shall be with effect from Thursday, 1st July, 2021 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended 30th June, 2021. The date of the Board Meeting of the Company for declaration of the Unaudited Financial Results for the quarter ended 30th June, 2021 will be intimated in due course. This is for your information and record.
Sun Pharma's Revlimid drug patent settlement does not enthuse Street
Celgene is granting Sun Pharma a licence to sell a limited quantity of the generic, which will begin after Mar'22 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to the settlement of patent litigation for generic Revlimid(r) (lenalidomide) in the US. Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to the settlement of patent litigation for generic Revlimid(r) (lenalidomide) in the US. Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015